Alzheimer's Disease Neuroimaging Initiative

描述（由申请人提供）：这个阿尔茨海默病神经影像学计划（ADNI）的主要目标是：1)开发改进的方法，这将导致统一的标准，用于获取阿尔茨海默病（AD）、轻度认知障碍（MCI）和老年对照患者的纵向、多位点磁共振成像（MRI）和正电子发射断层扫描（PET）数据。2)获得一个普遍可访问的数据存储库，它描述了大脑结构和代谢的纵向变化。同时，获取临床、认知和生物标志物数据，以验证成像替代品。3)在涉及这些患者群体的试验中，确定那些为确定治疗效果提供最大力量的方法。一个在阿尔茨海默病临床试验、MRI、PET、生物标志物和信息学方面具有丰富经验的研究团队已经组建。研究设计是对申请请求（RFA）的响应。项目的前六个月将致力于在所有40-45个参与地点建立统一的MRI和PET采集技术，然后开始受试者招募。如果有用，将评估和实施改进的MRI和PET量化方法。所有受试者将进行临床/认知评估，每6个月进行1.5 T结构MRI检查，持续2-3年。大约50%的受试者将在同一时间间隔进行18氟脱氧葡萄糖（FDG） PET扫描，25%的受试者（不进行PET扫描）将进行3特斯拉的MRI扫描。AD受试者（n=200）将在0、6、12、18和24个月时进行研究。将在0、6、12、18、24、30和36个月时对转化为AD的高风险MCI受试者（n= 400）进行研究。年龄匹配的对照组（n=200）将在0、6、12和24个月时进行研究。所有MRI和PET扫描将由神经成像中心的MRI和PET组件快速评估质量，以便在必要时对受试者进行重新扫描。所有临床数据将由加州大学圣地亚哥分校（UCSD） AD合作研究项目的临床中心收集、监测和存储。宾夕法尼亚大学将收集生物标志物样本。所有原始和处理过的图像数据都将存档于加州大学洛杉矶分校（UCLA）神经成像实验室（LONI）。试点研究将评估不同的图像处理方法来测量感兴趣的大脑区域。所有数据将由项目统计人员监测和分析，数据库查询将根据要求执行。所有临床、认知、成像和生物标记数据库将被连接起来，所有原始、处理和统计分析的数据将通过互联网全面、快速地向公众开放。本研究的结果将对未来AD和MCI试验的设计非常有用。

DESCRIPTION (provided by applicant): The major goals of this Alzheimer's Disease Neuroimaging Initiative (ADNI) are to: 1) Develop improved methods, which will lead to uniform standards for acquiring longitudinal, multi-site Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) data on patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and elderly controls. 2) Acquire a generally accessible data repository, which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical, cognitive and biomarker data for validation of imaging surrogates. 3) Determine those methods which provide maximum power to determine treatment effects in trials involving these patient groups. A team of investigators with considerable experience in AD clinical trials, MRI, PET, biomarkers and informatics has been assembled. Study design is in response to the Request For Applications (RFA). The first six months of the project will be devoted to establishing uniform MRI and PET acquisition techniques at all of the 40-45 participating sites, followed by initiation of subject recruitment. Improved methods for MRI and PET quantification will be assessed and implemented if useful. All subjects will have clinical/cognitive assessments and 1.5 T structural MRI every 6 months for 2-3 years. Approximately 50% of subjects will also have 18fluorodeoxyglucose (FDG) PET scans at the same time intervals and 25% of subjects (who do not also have PET) will have MRI at 3 Tesla. AD subjects (n=200) will be studied at 0, 6, 12, 18, and 24 months. MCI subjects at high risk for conversion to AD (n= 400) will be studied at 0, 6, 12, 18, 24, 30, and 36 months. Age matched controls (n=200) will be studied at 0, 6, 12, and 24 months. All MRI and PET scans will be rapidly assessed for quality by the MRI and PET components of the Neuroimaging Center so that subjects may be rescanned if necessary. All clinical data will be collected, monitored, and stored by the Clinical Center at the AD Cooperative Studies program at the University of California San Diego (UCSD). The University of Pennsylvania (UPenn) will collect biomarker samples. All raw and processed image data will be archived at The Laboratory of Neuroimaging (LONI) at the University of California Los Angeles (UCLA). Pilot studies will evaluate different image processing methods to measure brain regions of interest. All data will be monitored and analyzed by project statisticians, and data base queries will be performed on request. All clinical, cognitive, imaging, and biomarker databases will be linked and all raw, processed, and statistically analyzed data will be fully and rapidly accessible to the public through the Internet. The results of this study will be extremely useful for design of future AD and MCI trials.